HMGB1 and Parkinson disease: Additionally, systemic administration of neutralizing antibodies to HMGB1 has also been proven to inhibit the microglial activation, suppress secondary neuroinflammation and thus prevent the dopaminergic cell death upon neurotoxin exposure in PD models (Santoro et al., 2016; Sasaki et al., 2016).